Astrazeneca takes £13bn loan to fund Alexion deal | This is Money
Alexion Agrees to Work With Hedge Fund Elliott on Filling Board Seat - WSJ
Alexion (ALXN) Collaborates With Stealth BioTherapeutics | Investing.com
Alexion Pharmaceuticals: In The News And Moving Higher (NASDAQ:ALXN) | Seeking Alpha
ALEXION PHARMACEUTICALS, INC. : ALXN Stock Price | US0153511094 | MarketScreener
Biotech blastoff: Synageva up 112% on $8 B Alexion deal
Alexion Pharmaceuticals: Revising My Valuation (NASDAQ:ALXN) | Seeking Alpha
Skanska Announces 121 Seaport Fully Leased as Alexion Pharmaceuticals Moves Headquarters to the Office Development | www.usa.skanska.com
Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price? | Fierce Pharma
Alexion Pharmaceuticals: Revising My Valuation (NASDAQ:ALXN) | Seeking Alpha
Want a robust quality drug pipeline? – Pay super premium!: Alexion to acquire Synageva in an $8.4bn deal – BSIC | Bocconi Students Investment Club
Alexion Pharmaceuticals: Pipeline Diversification Outweighs The Patent Uncertainty (NASDAQ:ALXN) | Seeking Alpha
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases | Business Wire
Alexion sees shares jump amid reported activist pressure from Elliott Management - Boston Business Journal
AstraZeneca to buy Alexion in $39bn immunology deal | Financial Times
Alexion Pharmaceuticals Stock Forecast: up to 192.336 USD! - ALXN Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
Elliott Management Is Said Push for Changes at Alexion - The New York Times
Alexion Stock May Be Worth $197 in Buyout | Barron's
Alexion Pharmaceuticals Stock Forecast: up to 192.336 USD! - ALXN Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
Alexion Pharmaceuticals: Patent Resolution Is Too Little Too Late (NASDAQ:ALXN) | Seeking Alpha
Alexion's ambitions in rare diseases burning bright after takeover
Alexion Shares Surge After $39 Billion AstraZeneca Takeover - TheStreet
4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020
Alexion Pharmaceuticals: Revising My Valuation (NASDAQ:ALXN) | Seeking Alpha
AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven | Fierce Biotech
